ES2095672T3 - Procedimiento para la obtencion de la desacetil-10 bacatina iii. - Google Patents

Procedimiento para la obtencion de la desacetil-10 bacatina iii.

Info

Publication number
ES2095672T3
ES2095672T3 ES93921986T ES93921986T ES2095672T3 ES 2095672 T3 ES2095672 T3 ES 2095672T3 ES 93921986 T ES93921986 T ES 93921986T ES 93921986 T ES93921986 T ES 93921986T ES 2095672 T3 ES2095672 T3 ES 2095672T3
Authority
ES
Spain
Prior art keywords
desacetil
iii
bacatina
obtaining
appropriate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921986T
Other languages
English (en)
Inventor
Rodolphe Margraff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of ES2095672T3 publication Critical patent/ES2095672T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

PROCESO DE OBTENCION DE LA DESACETIL-10 BACATINA III A PARTIR DE LA DIFERENTES PARTES DEL TAJO (TAXUS SP.) POR EXTRACCION POR UN SOLVENTE ORGANICO APROPIADO DE LA SOLUCION ACUOSA OBTENIDA TRAS EL TRATAMIENTO CON AGUA DE LA PARTE APROPIADA DEL IF O POR ADSORCION DE LA SOLUCION ACUOSA SOBRE UN SOPORTE APROPIADO Y DESORCION DE LA DESACETIL-10 BACTAINA III POR UN SOLVENTE APROPIADO Y ACONTINUACION CRISTALIZACION SELECTIVA DE LA DESACETIL-10 BACATINA III.
ES93921986T 1992-10-05 1993-10-04 Procedimiento para la obtencion de la desacetil-10 bacatina iii. Expired - Lifetime ES2095672T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9211745A FR2696462B1 (fr) 1992-10-05 1992-10-05 Procédé d'obtention de la désacétyl-10 baccatine III.

Publications (1)

Publication Number Publication Date
ES2095672T3 true ES2095672T3 (es) 1997-02-16

Family

ID=9434123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921986T Expired - Lifetime ES2095672T3 (es) 1992-10-05 1993-10-04 Procedimiento para la obtencion de la desacetil-10 bacatina iii.

Country Status (30)

Country Link
US (2) US5393896A (es)
EP (1) EP0663909B1 (es)
JP (1) JP3299753B2 (es)
KR (1) KR100301238B1 (es)
CN (1) CN1041310C (es)
AT (1) ATE147381T1 (es)
AU (1) AU680440B2 (es)
CA (2) CA2470124C (es)
CZ (2) CZ286452B6 (es)
DE (1) DE69307333T2 (es)
DK (1) DK0663909T3 (es)
EE (1) EE03124B1 (es)
ES (1) ES2095672T3 (es)
FI (1) FI109797B (es)
FR (1) FR2696462B1 (es)
GE (1) GEP19981433B (es)
GR (1) GR3022229T3 (es)
HU (1) HU225969B1 (es)
LT (1) LT3465B (es)
LV (1) LV10620B (es)
MX (1) MX9305770A (es)
NO (1) NO310414B1 (es)
NZ (1) NZ256449A (es)
PL (1) PL173993B1 (es)
RU (1) RU2108330C1 (es)
SK (1) SK280335B6 (es)
TW (1) TW404944B (es)
UA (1) UA40601C2 (es)
WO (1) WO1994007881A1 (es)
ZA (1) ZA937312B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
FR2714053B1 (fr) * 1993-12-22 1996-03-08 Pf Medicament Procédé d'extraction et d'isolement de la 10-désacétylbaccatine III.
CN1112433A (zh) * 1994-05-24 1995-11-29 郭明 红豆杉属植物提取物及其应用
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
FR2736355B1 (fr) * 1995-07-07 1997-11-07 Pf Medicament Procede d'extraction et d'isolement de la 10-desacetylbaccatine iii
US5965752A (en) * 1996-08-23 1999-10-12 Institut National De La Recherche Scientifique Preparative scale isolation and purification of taxanes
US6111144A (en) 1997-08-21 2000-08-29 Florida State University Method for the synthesis of a taxane intermediate
US6066748A (en) * 1997-12-17 2000-05-23 Han; Man Woo Process of extracting TAXOL® from taxus cuspidata
ES2178369T3 (es) 1998-01-14 2002-12-16 Bristol Myers Squibb Co Nuevos complejos cristalinos dce baccatina iii con imidazol, 2-metilimidazol o isopropanol.
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
US6495705B2 (en) 2000-03-16 2002-12-17 Napro Biotherapeutics, Inc. Efficient process for the production of 10-DAB III by selective hydrazinolysis of various taxanes
US6281368B1 (en) 2000-03-16 2001-08-28 Napro Biotherapeutics, Inc. Simple and efficient hydrazinolysis of C-10 and C-13 ester functionalities of taxanes to obtain 10-DAB III
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
IT1320107B1 (it) * 2000-11-28 2003-11-18 Indena Spa Procedimento per la preparazione di derivati tassanici.
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
CA2440935A1 (en) 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2512170A1 (en) * 2002-12-31 2004-07-22 Natural Pharmaceuticals Inc. Pelletizing yew biomass for extraction of taxanes and other natural products
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2005037329A2 (en) * 2003-10-17 2005-04-28 Tyco Healthcare Group, Lp Surgical stapling device with independent tip rotation
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20060127510A1 (en) * 2003-12-30 2006-06-15 Natural Pharmaceuticals, Inc. Harvesting and pelletizing yew biomass for extraction of taxanes and other natural products
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US20050250954A1 (en) * 2004-05-04 2005-11-10 Phytogen Life Sciences Inc. Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes
US20050240036A1 (en) * 2004-04-23 2005-10-27 Phytogen Life Sciences Inc. Semi-synthesis of taxane intermediates from a mixture of taxanes
US20050272807A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel
DE602005012587D1 (de) * 2004-07-02 2009-03-19 Ivax Pharmaceuticals Sro Verfahren zur trennung von paclitaxel und cephalomannin
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
WO2007045093A1 (en) * 2005-10-21 2007-04-26 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Natural Resources Canada, Canadian Forest Service Preparation of taxanes
BRPI0709075A2 (pt) 2006-03-20 2011-10-11 Medigene Ag tratamento de cáncer de mama triplo receptor negativo
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
CN100404520C (zh) * 2006-08-15 2008-07-23 北京诺瑞医药技术有限公司 从欧洲红豆杉枝叶中提取分离10－去乙酰基巴卡汀ⅲ的方法
CN101230053B (zh) * 2007-12-04 2010-06-02 北京诺瑞医药技术有限公司 从红豆杉枝叶中超声提取分离10-去乙酰基巴卡汀ⅲ的方法
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
WO2013069027A1 (en) 2011-09-26 2013-05-16 Fresenius Kabi Oncology Ltd. Processes for the preparation of cabazitaxel involving c(7) -oh and c(13) -oh silylation or just c(7) -oh silylation
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN103508984B (zh) * 2013-10-22 2017-03-08 北京诺瑞医药技术有限公司 连续浸漉吸附富集法从红豆杉中提取10-dab的方法
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
HUE051255T2 (hu) 2014-02-19 2021-03-01 Aviv Therapeutics Inc Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
HUP1500603A2 (en) * 2015-12-11 2017-06-28 Rotachrom Tech Kft Process for the separation of 10-deacetyl baccatin iii
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
CN109640961B (zh) 2016-06-01 2021-11-02 施维雅知识产权英国有限公司 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
CN106397371A (zh) * 2016-08-31 2017-02-15 重庆市碚圣医药科技股份有限公司 一种用曼地亚红豆杉高产10‑dabⅲ的方法
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
JP7280827B2 (ja) 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
CA3090129A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
TW202038994A (zh) 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
WO2020165730A1 (en) 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP7716623B2 (ja) 2019-04-02 2025-08-01 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
WO2021116943A1 (en) 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
WO2021155028A1 (en) 2020-01-29 2021-08-05 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
CN116529267A (zh) 2020-06-04 2023-08-01 肯乔克蒂生物技术股份有限公司 Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
AU2021310520A1 (en) 2020-07-14 2023-02-16 Pfizer Inc. Recombinant vaccinia virus
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
WO2022103603A1 (en) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
US12187810B2 (en) 2020-11-20 2025-01-07 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
CN112694458A (zh) * 2020-12-29 2021-04-23 重庆臻源红豆杉发展有限公司 一种10-去乙酰基巴卡亭ⅲ提取纯化方法
US20250051471A1 (en) 2021-12-13 2025-02-13 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-Abcb1 Antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5019504A (en) * 1989-03-23 1991-05-28 The United States Of America As Represented By The Secretary Of Agriculture Production of taxol or taxol-like compounds in cell culture
US5175315A (en) * 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5380916A (en) 1990-11-02 1995-01-10 University Of Florida Method for the isolation and purification of taxane derivatives
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5279953A (en) * 1992-06-24 1994-01-18 Esca Genetics Corporation In vivo production of taxanes
FR2696463B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2703049B1 (fr) * 1993-03-22 1995-04-21 Rhone Poulenc Rorer Sa Procédé de purification des taxoïdes.

Also Published As

Publication number Publication date
RU95110662A (ru) 1996-12-27
WO1994007881A1 (fr) 1994-04-14
CA2470124A1 (fr) 1994-04-14
FR2696462B1 (fr) 1994-11-25
LT3465B (en) 1995-10-25
TW404944B (en) 2000-09-11
HU9500969D0 (en) 1995-06-28
ATE147381T1 (de) 1997-01-15
LV10620B (en) 1995-10-20
FI951590L (fi) 1995-04-04
CZ286593B6 (cs) 2000-05-17
CZ286452B6 (en) 2000-04-12
CZ84495A3 (en) 1995-09-13
LV10620A (lv) 1995-04-20
HU225969B1 (en) 2008-01-28
NO951281D0 (no) 1995-04-03
DE69307333D1 (de) 1997-02-20
CA2470124C (fr) 2007-08-07
US5736366A (en) 1998-04-07
GEP19981433B (en) 1998-10-30
FI951590A0 (fi) 1995-04-04
CA2146248C (fr) 2006-12-12
NO310414B1 (no) 2001-07-02
KR100301238B1 (ko) 2001-11-22
JP3299753B2 (ja) 2002-07-08
US5393896A (en) 1995-02-28
SK280335B6 (sk) 1999-12-10
ZA937312B (en) 1994-04-25
DE69307333T2 (de) 1997-04-30
GR3022229T3 (en) 1997-04-30
CN1085552A (zh) 1994-04-20
RU2108330C1 (ru) 1998-04-10
UA40601C2 (uk) 2001-08-15
JPH08501791A (ja) 1996-02-27
EP0663909A1 (fr) 1995-07-26
CA2146248A1 (fr) 1994-04-14
EP0663909B1 (fr) 1997-01-08
SK43195A3 (en) 1995-08-09
EE03124B1 (et) 1998-10-15
KR950703549A (ko) 1995-09-20
DK0663909T3 (es) 1997-01-27
HUT72678A (en) 1996-05-28
FI109797B (fi) 2002-10-15
MX9305770A (es) 1994-05-31
NO951281L (no) 1995-04-03
PL173993B1 (pl) 1998-05-29
FR2696462A1 (fr) 1994-04-08
CN1041310C (zh) 1998-12-23
AU680440B2 (en) 1997-07-31
LTIP1398A (en) 1994-11-25
PL308243A1 (en) 1995-07-24
NZ256449A (en) 1996-09-25
AU5115493A (en) 1994-04-26

Similar Documents

Publication Publication Date Title
ES2095672T3 (es) Procedimiento para la obtencion de la desacetil-10 bacatina iii.
AR026302A1 (es) Un metodo para estabilizar solventes siliconados para la limpieza en seco, un adsorbente y un proceso de limpieza en seco.
FR2629818B1 (fr) Procede de preparation du taxol
MX9301569A (es) Procedimiento de extraccion de compuestos organicos a partir de soluciones acuosas.
CO4820399A1 (es) Material absorbente y metodo de obtencion . .
MX167139B (es) Procedimiento para la extraccion de disolventes
IT7828071A0 (it) Processo per la separazione di contaminanti polimerici da soluzioni acquose assorbenti usate per trattare correnti gassose contenenti gas organici.
ES2030379T3 (es) Procedimiento de recuperacion del anhidrido maleico de mezclas gaseosas de reaccion.
MX9306653A (es) Proceso para recuperar azufre e hidrogeno a partir de sulfuro de hidrogeno.
ES2077996T3 (es) Procedimiento para la purificacion y la recuperacion de acido ortofosforico por extraccion liquido-liquido.
BR8802018A (pt) Processo de eliminacao de radioatividade de uma solucao aquosa que inclui um nitrato de radio
ES2024461B3 (es) Procedimiento para el trasvase automatico de precintos de alambre de botellas de champaña desde un puesto de tratamiento a una descarga, o desde una descarga a un puesto de tratamiento ulterior, asi como una disposicion para el desarrollo del procedimiento.
AR036017A1 (es) Proceso para la preparacion de cilastatina sodica pura en una forma amorfa
ES2033830T3 (es) Procedimiento para producir compuestos macrolidos.
ITMI20022409A1 (it) Procedimento per la purificazione di 1, 4-butandiolo mononitrato.
JPS524650A (en) Purifying method for polluted water
PT82935A (fr) Procede de preparation des derives n-methyles du lysergol et du methoxy-10 alpha lumilysergol
MX9206926A (es) Procedimiento para el tratamiento de aguas residuales que contienen compuesto de rodio, derivados de fosfinas organicas y otros contaminantes disueltos.
ES2001279A6 (es) Procedimiento para la separacion del arsenico de soluciones acuosas acidas que lo contengan
IT1238003B (it) Processo per la rigenerazione di carbone attivo
AR213388A1 (es) Procedimiento para la recuperacion de glucagon,de las aguas madres de cristalizacion alcalina de la insulina
ES1009822Y (es) Dispositivo para el tratamiento de la impotencia sexual de hombres.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 663909

Country of ref document: ES